Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Secondary lymphoid organs (SLOs), such as the lymph nodes and spleen ... through the BCR, B cells can transport antigen to FDCs, as illustrated by splenic marginal-zone B cells.

is a mature B-cell hematological malignancy characterized by progressive clonal proliferation of B lymphocytes in the peripheral blood, bone marrow, and lymph nodes. 1 CLL histology plays a key role ...

4 Institute of Pathology ... of CD19-CAR T-cell therapy is presumably based on deep tissue depletion of B cells; however, such effect has not been proven in humans in vivo. Methods Sequential ...

A lymph node biopsy is also required in cases of unexplained ... lymphoma)/Waldenström macroglobulinemia, marginal zone lymphoma, or other known lymphoma entities. Nodular B-cell aggregates were ...

4 Adaptive immunity, which is only found in vertebrates, is mediated by T and B cells which ... as draining lymph nodes 5 Follicle associated epithelium, which covers organised lymphoid tissue in the ...

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of ...

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments ...

Scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood -- known as the tertiary lymphoid structure -- where they become ...

Researchers observed an increase in both CXCR4 and CD5 levels as the cells progressed to later stages of the cell cycle, particularly in the S/G2/M phases.

Dr. Heidenreich notes that among the 86% of seminoma CSI patients, 15-30% relapse, of which 95% relapse in the retroperitoneum, nearly all relapses have good prognosis, and these patients are now CS ...